Literature DB >> 3549845

Dopamine and serotonin systems in human and rodent brain: effects of age and neurodegenerative disease.

D G Morgan, P C May, C E Finch.   

Abstract

The nonpathological age-related changes in the dopamine- and serotonin-containing neurotransmitter systems in human and rodent brain are reviewed. The dopamine system exhibits age-related declines both presynaptically and postsynaptically. Presynaptically, both the levels of dopamine and the number of midbrain dopamine-containing neurons decline by up to 50% at advanced ages in the absence of neurological disease. Postsynaptically, the density of D-2 dopamine receptors decreases by 40%, while D-1 dopamine receptors either increase (man) or remain stable (rodents). Additional reductions of dopamine levels and D-2 receptors have been reported in Alzheimer's disease (AD), but these changes are relatively small, and not consistently observed. The levels of serotonin appear stable during normal aging, and presynaptic markers such as (3H)imipramine binding may actually increase. In human brain, the two major classes of serotonin receptor (S-1 and S-2) decrease by 30 to 50% over the lifespan. In AD, both presynaptic and postsynaptic markers of the serotonin system are reduced, including a loss of the serotonin-containing raphe neurons. The additional loss of serotonin receptors in AD approaches 80% when compared with young normals. A hypothesis is presented to explain the typically young age at onset of schizophrenia (usually before 30 years of age) and the older age at onset of parkinsonism (rarely before 50 years of age) within the context of normal age-related declines in the dopamine system occurring in the absence of neurological disorders. The possibility that chronic cocaine abuse might accelerate the development of parkinsonism is discussed.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3549845     DOI: 10.1111/j.1532-5415.1987.tb04641.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  32 in total

Review 1.  Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II).

Authors:  Rashmi R Shah
Journal:  Br J Clin Pharmacol       Date:  2004-11       Impact factor: 4.335

2.  Brain aging phenomena in migrating sockeye salmon Oncorhynchus nerka nerka.

Authors:  M E Götz; C R Malz; A Dirr; D Blum; W Gsell; S Schmidt; R Burger; S Pohli; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  2005-01-31       Impact factor: 3.575

3.  Behavioural responses to the selective D1-dopamine receptor agonist R-SK&F 38393 and the selective D2-agonist RU 24213 in young compared with aged rats.

Authors:  A G Molloy; J L Waddington
Journal:  Br J Pharmacol       Date:  1988-10       Impact factor: 8.739

Review 4.  Genetics and the pathobiology of ageing.

Authors:  G M Martin
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1997-12-29       Impact factor: 6.237

5.  Role of ERK1, 2, and 5 in dopamine neuron survival during aging.

Authors:  Mayur S Parmar; Juliann D Jaumotte; Stephanie L Wyrostek; Michael J Zigmond; Jane E Cavanaugh
Journal:  Neurobiol Aging       Date:  2013-10-23       Impact factor: 4.673

6.  Human Striatal Dopaminergic and Regional Serotonergic Synaptic Degeneration with Lewy Body Disease and Inheritance of APOE ε4.

Authors:  Nadia Postupna; Caitlin S Latimer; Eric B Larson; Emily Sherfield; Julie Paladin; Carol A Shively; Matthew J Jorgensen; Rachel N Andrews; Jay R Kaplan; Paul K Crane; Kathleen S Montine; Suzanne Craft; C Dirk Keene; Thomas J Montine
Journal:  Am J Pathol       Date:  2017-02-16       Impact factor: 4.307

7.  Dynapenia and aging: an update.

Authors:  Todd M Manini; Brian C Clark
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2011-03-28       Impact factor: 6.053

Review 8.  The ageing brain, neuroleptic drugs and the enigma of schizophrenia.

Authors:  J L Waddington
Journal:  Ir J Med Sci       Date:  1988-05       Impact factor: 1.568

9.  Soluble beta amyloid(1-42): a critical player in producing behavioural and biochemical changes evoking depressive-related state?

Authors:  M Colaianna; P Tucci; M Zotti; M G Morgese; S Schiavone; S Govoni; V Cuomo; L Trabace
Journal:  Br J Pharmacol       Date:  2010-03-09       Impact factor: 8.739

10.  Difference in muscle quality over the adult life span and biological correlates in the Baltimore Longitudinal Study of Aging.

Authors:  Ann Zenobia Moore; Giorgio Caturegli; E Jeffrey Metter; Sokratis Makrogiannis; Susan M Resnick; Tamara B Harris; Luigi Ferrucci
Journal:  J Am Geriatr Soc       Date:  2014-01-17       Impact factor: 5.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.